Abbott Pays Top Dollar For Galapagos’ Autoimmune Drug
As its pharma division separates from its diversified medical products unit, Abbott obtains another drug that could succeed Humira in rheumatoid arthritis and related indications.
You may also be interested in...
Ablynx stands to get $840 million and double-digit royalties under a global license deal with AbbVie to develop and commercialize the Belgian group’s anti-IL-6R candidate ALX-0061 to treat inflammatory diseases. The transaction brings a big boost to the biotech’s prospects.
The pharma did not offer much detail on plans to split into two publicly traded companies during its quarterly call, but did shed some light on its HCV pipeline one day ahead of EASL.
Abbott announces that its research-based pharmaceutical division will be called AbbVie once it splits off at the end of the year.